spot_img
Tuesday, June 28, 2022
No menu items!
More
    spot_img
    HomeBusinessEugia Pharma gets USFDA nod for prostate cancer drug

    Eugia Pharma gets USFDA nod for prostate cancer drug

    -

    News

    Aurobindo Pharma subsidiary to make and market leuprolide acetate injection

    Eugia Pharma Specialties Limited, a wholly owned subsidiary of Aurobindo Pharma Ltd, has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market leuprolide acetate injection.

    The product is a bioequivalent and therapeutical equivalent of the reference listed drug (RLD) Lupron injection of AbbVie Endocrinology Inc (AbbVie).

    The product will be launched this month. It has an estimated market size of $83 million for the 12 months ending April 2022, according to IQVIA, Hyderabad-based Aurobindo Pharma said in a release.

    This is the 140th abbreviated new drug application, or ANDA (including eight tentative approvals received), from the Eugia Pharma Specialty Group, which manufactures both oral and sterile speciality products. 

    Leuprolide acetate injection is used to treat symptoms associated with advanced prostate cancer .

    Published on June 07, 2022

    You May Also Like

    Recommended for you

    Related articles

    LEAVE A REPLY

    Please enter your comment!
    Please enter your name here

    Stay Connected

    0FansLike
    0FollowersFollow
    3,370FollowersFollow
    0SubscribersSubscribe
    spot_img

    Latest posts